Abrdn Life Sciences Investors (HQL) News Today

Abrdn Life Sciences Investors (NYSE:HQL) announced a quarterly dividend on Monday, August 12th. Investors of record on Friday, August 23rd will be paid a dividend of 0.49 per share on Monday, September 30th. This represents a $1.96 dividend on an annualized basis and a dividend yield of 12.92%. The ex-dividend date is Friday, August 23rd. This is a boost from Abrdn Life Sciences Investors's previous quarterly dividend of $0.48.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) saw a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 264,100 shares, an increase of 4,978.8% from the July 15th total of 5,200 shares. Based on an average daily trading volume, of 96,800 shares, the days-to-cover ratio is currently 2.7 days.

Few people pay much attention to the management team of a closed-end fund (CEF). But it’s becoming a much more critical factor driving CEF upside (and

Cetera Advisors LLC purchased a new stake in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 141,526 shares of the company's stock, valued at approximately $1,929,000.

Cornerstone Advisors LLC trimmed its position in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 93.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,914 shares of the company's stock after selling 462,426 shares

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) Director Rose Dimartino acquired 1,000 shares of Abrdn Life Sciences Investors stock in a transaction dated Tuesday, July 16th. The shares were bought at an average cost of $15.53 per share, with a total value of $15,530.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $15,530. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 2,400 shares of the stock in a transaction that occurred on Wednesday, June 12th. The stock was acquired at an average cost of $13.88 per share, with a total value of $33,312.00. Following the completion of the purchase, the insider now owns 3,407,612 shares of the company's stock, valued at $47,297,654.56. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 9,704 shares of Abrdn Life Sciences Investors stock in a transaction that occurred on Monday, June 10th. The stock was bought at an average cost of $13.71 per share, for a total transaction of $133,041.84. Following the purchase, the insider now directly owns 3,403,173 shares in the company, valued at $46,657,501.83. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 9,598 shares of Abrdn Life Sciences Investors stock in a transaction on Thursday, June 6th. The shares were bought at an average price of $13.80 per share, for a total transaction of $132,452.40. Following the purchase, the insider now owns 3,389,706 shares of the company's stock, valued at $46,777,942.80. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 33,357 shares of the business's stock in a transaction on Tuesday, June 4th. The shares were bought at an average cost of $13.50 per share, for a total transaction of $450,319.50. Following the completion of the transaction, the insider now directly owns 3,354,025 shares in the company, valued at approximately $45,279,337.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 73,600 shares, an increase of 26.0% from the April 30th total of 58,400 shares. Based on an average trading volume of 83,200 shares, the short-interest ratio is currently 0.9 days.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 1,303 shares of the firm's stock in a transaction that occurred on Thursday, May 23rd. The stock was purchased at an average price of $13.50 per share, with a total value of $17,590.50. Following the completion of the purchase, the insider now owns 3,251,883 shares in the company, valued at $43,900,420.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL) declared a quarterly dividend on Thursday, May 9th. Stockholders of record on Thursday, May 23rd will be paid a dividend of 0.48 per share on Friday, June 28th. This represents a $1.92 annualized dividend and a dividend yield of 13.62%. The ex-dividend date is Wednesday, May 22nd. This is a boost from Abrdn Life Sciences Investors's previous quarterly dividend of $0.39.

Cornerstone Advisors LLC raised its position in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 73.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 494,340 shares of the company's stock after purchasing an add

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 34,755 shares of the business's stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average cost of $14.19 per share, with a total value of $493,173.45. Following the completion of the purchase, the insider now directly owns 3,250,580 shares of the company's stock, valued at approximately $46,125,730.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 57,862 shares of the stock in a transaction dated Friday, May 10th. The stock was acquired at an average price of $13.86 per share, for a total transaction of $801,967.32. Following the completion of the transaction, the insider now directly owns 3,215,825 shares of the company's stock, valued at $44,571,334.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 10,986 shares of the firm's stock in a transaction on Wednesday, May 8th. The stock was purchased at an average cost of $13.70 per share, for a total transaction of $150,508.20. Following the completion of the acquisition, the insider now owns 3,140,590 shares in the company, valued at $43,026,083. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 10,713 shares of Abrdn Life Sciences Investors stock in a transaction dated Monday, May 6th. The shares were bought at an average price of $13.62 per share, with a total value of $145,911.06. Following the completion of the acquisition, the insider now directly owns 3,079,443 shares of the company's stock, valued at $41,942,013.66. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 26,274 shares of the business's stock in a transaction dated Thursday, May 2nd. The shares were bought at an average price of $13.46 per share, for a total transaction of $353,648.04. Following the completion of the acquisition, the insider now owns 3,068,730 shares in the company, valued at $41,305,105.80. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 16,573 shares of the firm's stock in a transaction that occurred on Tuesday, April 30th. The shares were bought at an average price of $13.13 per share, with a total value of $217,603.49. Following the acquisition, the insider now directly owns 3,042,204 shares in the company, valued at $39,944,138.52. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 120,304 shares of the stock in a transaction that occurred on Friday, April 26th. The shares were bought at an average price of $13.00 per share, with a total value of $1,563,952.00. Following the completion of the transaction, the insider now owns 3,025,602 shares in the company, valued at $39,332,826. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 20,529 shares of the firm's stock in a transaction that occurred on Wednesday, April 24th. The stock was purchased at an average cost of $13.12 per share, with a total value of $269,340.48. Following the completion of the transaction, the insider now owns 2,807,724 shares in the company, valued at $36,837,338.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Wolverine Asset Management LLC decreased its holdings in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 35.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 207,392

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 2,022 shares of the stock in a transaction dated Monday, April 22nd. The shares were bought at an average cost of $12.88 per share, for a total transaction of $26,043.36. Following the acquisition, the insider now owns 2,738,992 shares in the company, valued at approximately $35,278,216.96. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 81,738 shares of the company's stock in a transaction on Thursday, April 18th. The shares were purchased at an average price of $12.80 per share, with a total value of $1,046,246.40. Following the completion of the purchase, the insider now directly owns 2,694,511 shares of the company's stock, valued at $34,489,740.80. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.

Allspring Global Investments Holdings LLC lifted its position in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 30.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 454,154 shares of the company's stock afte

Raymond James Financial Services Advisors Inc. grew its stake in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 183.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 131,077 shar